Treatment with anti-angiogenic agents is considered to reverse VEGF induced promotion of Tregs; as expected, bevacizumab demonstrated inhibition of Treg accumulation in peripheral blood of patients with metastatic colorectal cancer [124]. This evidence concerns the gene VEGFA and metastatic colorectal cancer.